Saloni Mangal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Saloni Mangal has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Avijit Mazumder
Department of Pharmacology, Noida Institute of Engineering and Technology (Pharmacy Institute), Knowledge Park-II, Greater Noida, 201306 Uttar Pradesh, India
2 shared publications - Salahuddin Salahuddin
Department of Pharmaceutical Chemistry, Noida Institute of Engineering and Technology (Pharmacy Institute), 19, Knowledge Park II, Greater Noida 201306, Uttar Pradesh, India
2 shared publications - Abhijit Debnath
Department of Pharmaceutics, Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida, Uttar Pradesh, 201310, India
1 shared publication - Anil Kumar Singh
Department of Dravyaguna, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India
1 shared publication Avijit Mazumder
Department of Pharmaceutical Chemistry, Noida Institute of Engineering and Technology (Pharmacy Institute), Plot no.19, Knowledge Park-2, Greater Noida, 201306, Uttar Pradesh, India
1 shared publication- Hema Chaudhary
School of Medical & Allied Sciences, K R Mangalam University, Gurugram, India
1 shared publication
Latest Publications
- 10 June 2025
- Published by Bentham Science Publishers Ltd. in Medicinal Chemistry
- Vol. 21, 1-21
Optimized Strategies for the Synthesis and Structure-Activity Relationship of Imidazole as an Antiepileptic Drug
Imidazole is believed to be a highly multifunctional compound in the medicinal andbiological sectors. This literature focuses on information about the synthesis and anticonvulsantactivity presented by the imidazole nucleus. Epilepsy is a chronic brain disorder including multipleseizures and brain cell abnormalities. Due to its old and less effective treatment, with theincrease in the number of patients suffering from epilepsy, researchers need to concentrate onthe emergence of finding new treatments for epilepsy. Imidazole-containing analogs are foundto be significant in the field of medicinal chemistry and the treatment for epilepsy. These studiesprompted us to synthesize and provide insights into developing new imidazole-bearing antiepilepticdrugs.
- 10 June 2025
- Published by Bentham Science Publishers Ltd. in Medicinal Chemistry
- Vol. 21, 1-21
Optimized Strategies for the Synthesis and Structure-Activity Relationship of Imidazole as an Antiepileptic Drug
Imidazole is believed to be a highly multifunctional compound in the medicinal andbiological sectors. This literature focuses on information about the synthesis and anticonvulsantactivity presented by the imidazole nucleus. Epilepsy is a chronic brain disorder including multipleseizures and brain cell abnormalities. Due to its old and less effective treatment, with theincrease in the number of patients suffering from epilepsy, researchers need to concentrate onthe emergence of finding new treatments for epilepsy. Imidazole-containing analogs are foundto be significant in the field of medicinal chemistry and the treatment for epilepsy. These studiesprompted us to synthesize and provide insights into developing new imidazole-bearing antiepilepticdrugs.
- 16 May 2025
- Published by Taylor & Francis in Synthetic Communications
- Vol. 55 (17) , 1281-1305
Significant advances in catalytic strategies for the synthesis of trisubstituted imidazoles: a review
- 16 May 2025
- Published by Taylor & Francis in Synthetic Communications
- Vol. 55 (17) , 1281-1305
Significant advances in catalytic strategies for the synthesis of trisubstituted imidazoles: a review
- 19 December 2024
- Published by Taylor & Francis in Journal of Receptors and Signal Transduction
- Vol. 45 (1) , 1-21
Quest for discovering novel CDK12 inhibitor
CDK12 is essential for cellular processes like RNA processing, transcription, and cell cycle regulation, inhibiting cancer cell growth and facilitating macrophage invasion. CDK12 is a significant oncogenic factor in various cancers, including HER2-positive breast cancer, Anaplastic thyroid carcinoma, Hepatocellular carcinoma, prostate cancer, and Ewing sarcoma. It is also regarded as a potential biomarker, emphasizing its broader significance in oncology. Targeting CDK12 offers a promising strategy to develop therapy. Various monoclonal antibodies have drawn wide attention, but they are expensive compared to small-molecule inhibitors, limiting their accessibility and affordability for patients. Consequently, this research aims to identify effective CDK12 inhibitors using comprehensive high-throughput virtual screening. RASPD protocol has been employed to screen three different databases against the target followed by drug-likeness, molecular docking, ADME, toxicity, Consensus molecular docking, MD Simulation, and in-vitro studies MTT assay. The research conducted yielded one compound ZINC11784547 has demonstrated robust binding affinity, favorable ADME features, less toxicity, remarkable stability, and cytotoxic effect. The identified compound holds promise for promoting cancer cell death through CDK12 inhibition.
- 19 December 2024
- Published by Taylor & Francis in Journal of Receptors and Signal Transduction
- Vol. 45 (1) , 1-21
Quest for discovering novel CDK12 inhibitor
CDK12 is essential for cellular processes like RNA processing, transcription, and cell cycle regulation, inhibiting cancer cell growth and facilitating macrophage invasion. CDK12 is a significant oncogenic factor in various cancers, including HER2-positive breast cancer, Anaplastic thyroid carcinoma, Hepatocellular carcinoma, prostate cancer, and Ewing sarcoma. It is also regarded as a potential biomarker, emphasizing its broader significance in oncology. Targeting CDK12 offers a promising strategy to develop therapy. Various monoclonal antibodies have drawn wide attention, but they are expensive compared to small-molecule inhibitors, limiting their accessibility and affordability for patients. Consequently, this research aims to identify effective CDK12 inhibitors using comprehensive high-throughput virtual screening. RASPD protocol has been employed to screen three different databases against the target followed by drug-likeness, molecular docking, ADME, toxicity, Consensus molecular docking, MD Simulation, and in-vitro studies MTT assay. The research conducted yielded one compound ZINC11784547 has demonstrated robust binding affinity, favorable ADME features, less toxicity, remarkable stability, and cytotoxic effect. The identified compound holds promise for promoting cancer cell death through CDK12 inhibition.